Somapacitan

帕西生长激素

Report date: 2025/12/30 14:26:21

Base Information

Drug NameSomapacitan
Drug Alias Name帕西生长素somapacitanAlbumin-binding somatropinLong-acting somatropinLong-acting growth hormone +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionGrowth hormone receptor agonists
TargetsGrowth hormone receptor
Therapy Area/IndicationsGrowth hormone deficiencyIdiopathic short statureFailure to Thrive +[8] 
Global Approved IndicationsGrowth hormone deficiency
Approved Indications in ChinaGrowth hormone deficiency
Original Approved Country/TerritoryUnited States
Original Approved Date2020/08/28
Country/TerritoryMainland China(BOAO LECHENG)BelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesChildren'S National Research InstituteNovo Nordisk IncNovo Nordisk A/S +[5] 
Inactive CompaniesN/A
Active IndicationsGrowth hormone deficiencyIdiopathic short statureFailure to Thrive +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeH01AC01
Related LinksN/A